 SAN DIEGO, Aug. 09, 2021 GLOBE NEWSWIRE -- AnaptysBio, Inc. Nasdaq: ANAB, a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the second quarter ended June 30, 2021 and provided pipeline updates. 